[go: up one dir, main page]

PE20140105A1 - Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos - Google Patents

Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos

Info

Publication number
PE20140105A1
PE20140105A1 PE2013000359A PE2013000359A PE20140105A1 PE 20140105 A1 PE20140105 A1 PE 20140105A1 PE 2013000359 A PE2013000359 A PE 2013000359A PE 2013000359 A PE2013000359 A PE 2013000359A PE 20140105 A1 PE20140105 A1 PE 20140105A1
Authority
PE
Peru
Prior art keywords
pridopidine
deuterated
analogues useful
dopaminergic stabilizers
useful
Prior art date
Application number
PE2013000359A
Other languages
English (en)
Inventor
Clas Sonesson
Original Assignee
Ivax Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivax Int Gmbh filed Critical Ivax Int Gmbh
Publication of PE20140105A1 publication Critical patent/PE20140105A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN ANALOGO DEUTERADO DE 4-(3-METANOSULFONIL-FENIL)-1-PROPIL-PIPERIDINA (PRIDOPIDINA) DE FORMULA (I), DONDE AL MENOS UNO DE R1 A R23 ES DEUTERIO Y EL RESTO DE R1 A R23 SON HIDROGENO. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES UTIL EN EL TRATAMIENTO DE LA ENFERMEDAD DE HUNTINGTON
PE2013000359A 2010-09-03 2011-08-31 Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos PE20140105A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201070385 2010-09-03
US38085110P 2010-09-08 2010-09-08

Publications (1)

Publication Number Publication Date
PE20140105A1 true PE20140105A1 (es) 2014-02-14

Family

ID=44653278

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000359A PE20140105A1 (es) 2010-09-03 2011-08-31 Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos

Country Status (18)

Country Link
US (5) US20130197031A1 (es)
EP (1) EP2611759A1 (es)
JP (1) JP2013536825A (es)
KR (1) KR20140008297A (es)
CN (1) CN103249697B (es)
AU (2) AU2011298382A1 (es)
BR (1) BR112013005125A2 (es)
CA (1) CA2810092A1 (es)
CL (1) CL2013000604A1 (es)
EA (1) EA201390332A1 (es)
IL (1) IL224776A (es)
MX (1) MX2013002453A (es)
NZ (1) NZ608120A (es)
PE (1) PE20140105A1 (es)
PH (1) PH12013500406A1 (es)
SG (2) SG188298A1 (es)
WO (1) WO2012028635A1 (es)
ZA (1) ZA201301902B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
NZ580856A (en) * 2007-04-12 2011-11-25 Nsab Af Neurosearch Sweden Ab N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
PE20140105A1 (es) * 2010-09-03 2014-02-14 Ivax Int Gmbh Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos
AU2012306386B2 (en) 2011-09-07 2017-06-15 Teva Pharmaceuticals International Gmbh Polymorphic form of pridopidine hydrochloride
WO2013086425A1 (en) 2011-12-08 2013-06-13 IVAX International GmbH The hydrobromide salt of pridopidine
EP2844346B1 (en) 2012-04-04 2020-01-01 Prilenia Neurotherapeutics Ltd. Pharmaceutical compositions for combination therapy
EP2897615A4 (en) 2012-09-18 2016-04-27 Auspex Pharmaceuticals Inc PHARMACOKINETIC FORMULATIONS OF DEUTERATED BENZOCHINOL INHIBITORS OF THE VESICLE MONOAMINE TRANSPORTER 2
HUE054783T2 (hu) 2013-06-21 2021-09-28 Prilenia Neurotherapeutics Ltd Pridopidin Huntington-kór kezelésében
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
US10166183B2 (en) 2014-02-07 2019-01-01 Auspex Pharmaceuticals, Inc. Pharmaceutical formulations
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP3236964A4 (en) 2014-12-22 2018-09-19 Teva Pharmaceuticals International GmbH L-tartrate salt of pridopidine
EP4282479A3 (en) 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
HK1249860A1 (zh) * 2015-03-06 2018-11-16 奥斯拜客斯制药有限公司 用於治疗异常不自主运动障碍的方法
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017147366A1 (en) 2016-02-24 2017-08-31 Teva Pharmaceuticals International Gmbh Treatment of neurodegenerative eye disease using pridopidine
BR112019003731A2 (pt) 2016-08-24 2019-07-16 Prilenia Therapeutics Dev Ltd aplicação de pridopidina para tratamento de distonias
CA3035092C (en) 2016-08-24 2022-05-31 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating functional decline
DK3512517T3 (da) 2016-09-15 2025-06-10 Prilenia Neurotherapeutics Ltd Anvendelse af pridopidin til behandling af angst og depression
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
CA3036984C (en) 2016-09-16 2023-07-18 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating rett syndrome
EP3570940B1 (en) 2017-01-20 2023-12-13 Prilenia Neurotherapeutics Ltd. Pridopidine for use in the treatment of fragile x syndrome
US10459055B2 (en) * 2017-04-07 2019-10-29 Case Western Reserve University System and method for reduced field of view MR fingerprinting for parametric mapping
RS67438B1 (sr) 2017-08-14 2025-12-31 Prilenia Neurotherapeutics Ltd Lečenje amiotrofne lateralne skleroze pridopidinom
MX2020002310A (es) 2017-08-30 2020-09-17 Prilenia Neurotherapeutics Ltd Formas de dosificacion de alta concentracion de pridopidina.
MX383462B (es) 2017-09-08 2025-03-14 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento de las discinesias inducidas por fármacos
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
CN121489943A (zh) 2019-02-04 2026-02-10 普瑞尼亚神经治疗有限公司 用于帕金森氏病和与帕金森症相关的其它疾病的低剂量普利多匹定
JP7701931B2 (ja) 2020-02-13 2025-07-02 プリレニア ニューロセラピューティクス リミテッド プリドピジンおよび他の活性薬剤を使用して筋萎縮性側索を治療するための併用療法
EP4146208A4 (en) 2020-05-04 2024-05-22 Prilenia Neurotherapeutics Ltd. Treatment of viral infection, disease or disorder using a selective s1r agonist
EP4153111A4 (en) 2020-05-20 2024-06-12 Nthalmic Holding Pty Ltd METHODS AND APPARATUS FOR MANAGING MEIBOMIUS GLAND DEFICIENCIES
TW202208373A (zh) * 2020-05-20 2022-03-01 美商瑟泰戈治療學股份有限公司 環經氘化之加波沙朵及其用於治療精神病症用途

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
ES2193921T3 (es) * 1999-12-03 2003-11-16 Pfizer Prod Inc Compuestos de sulfamoilheteroaril-pirazol como agentes antinflamatorios/analgesicos.
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
DE10123129A1 (de) * 2001-05-02 2002-11-14 Berolina Drug Dev Ab Svedala Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
US7004629B2 (en) 2003-07-26 2006-02-28 Arthur Joseph Shrader Method and apparatus for hanging a resealable bag
DK1773772T3 (da) 2004-06-08 2010-09-13 Nsab Af Neurosearch Sweden Ab Nye disubstituerede phenylpiperidiner/piperaziner som modulatorer af dopaminneurotransmission
ES2659577T3 (es) 2004-10-13 2018-03-16 Teva Pharmaceuticals International Gmbh Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina
BRPI0617987A2 (pt) * 2005-10-06 2011-08-16 Auspex Pharmaceuticals Inc composição, composição farmacêutica, forma de dosagem efervescente, composição farmacêutica oral de comprimidos unitários múltiplos, forma de dosagem farmacêutica de liberação prolongada, forma de dosagem farmacêutica revestida entérica, forma de dosagem farmacêutica estável para administração oral a sujeitos mamìferos, método para tratamento de doenças relacionadas a ácido gástrico pela inibição de secreção de ácido gástrico, método para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori, processo para preparar um composto da fórmula 3, processo para preparar um composto da fórmula 5, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relacionadas a ácido gástrico, pela inibição de secreção de ácido gástrico, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relecionadas a ácido gástrico pela inibição de secreção de ácido gástrico
US20070112031A1 (en) 2005-11-14 2007-05-17 Gant Thomas G Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
CN101360742A (zh) * 2005-11-14 2009-02-04 奥斯拜客斯制药有限公司 具有血清素源性活性和增强的治疗特性的取代苯基哌啶
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
NZ580856A (en) 2007-04-12 2011-11-25 Nsab Af Neurosearch Sweden Ab N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
WO2008155357A2 (en) 2007-06-18 2008-12-24 A. Carlsson Research Ab Use of dopamine stabilizers
US8288414B2 (en) * 2007-09-12 2012-10-16 Deuteria Pharmaceuticals, Inc. Deuterium-enriched lenalidomide
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
PE20140105A1 (es) * 2010-09-03 2014-02-14 Ivax Int Gmbh Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos
AU2012306386B2 (en) 2011-09-07 2017-06-15 Teva Pharmaceuticals International Gmbh Polymorphic form of pridopidine hydrochloride
WO2013086425A1 (en) 2011-12-08 2013-06-13 IVAX International GmbH The hydrobromide salt of pridopidine
EP2844346B1 (en) 2012-04-04 2020-01-01 Prilenia Neurotherapeutics Ltd. Pharmaceutical compositions for combination therapy
BR112015006093A2 (pt) 2012-09-27 2017-07-04 Teva Pharma combinação de rasagilina e pridopidine para o tratamento de desordens neurodegenerativas, particularmente na doença de huntington
MX2015003608A (es) 2012-09-27 2015-06-05 Teva Pharma Combinacion de laquinimod y pridopidina para tratar trastornos neurodegenerativos.
HUE054783T2 (hu) 2013-06-21 2021-09-28 Prilenia Neurotherapeutics Ltd Pridopidin Huntington-kór kezelésében
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
US20150202302A1 (en) 2014-01-22 2015-07-23 IVAX International GmbH Modified release formulations of pridopidine
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP3236964A4 (en) 2014-12-22 2018-09-19 Teva Pharmaceuticals International GmbH L-tartrate salt of pridopidine
EP4282479A3 (en) 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
EP3324967A4 (en) 2015-07-22 2019-03-20 Prilenia Therapeutics Development Ltd. PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME
WO2017015515A1 (en) 2015-07-23 2017-01-26 Knowles Electronics, Llc Microphone with temperature sensor
WO2017147366A1 (en) 2016-02-24 2017-08-31 Teva Pharmaceuticals International Gmbh Treatment of neurodegenerative eye disease using pridopidine
CA3035092C (en) 2016-08-24 2022-05-31 Prilenia Therapeutics Development Ltd. Use of pridopidine for treating functional decline
BR112019003731A2 (pt) 2016-08-24 2019-07-16 Prilenia Therapeutics Dev Ltd aplicação de pridopidina para tratamento de distonias
DK3512517T3 (da) 2016-09-15 2025-06-10 Prilenia Neurotherapeutics Ltd Anvendelse af pridopidin til behandling af angst og depression
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
BR112019005178A2 (pt) 2016-09-16 2019-07-02 Cargill Inc levedura geneticamente modificada, e, processo para produzir etanol.
EP3570940B1 (en) 2017-01-20 2023-12-13 Prilenia Neurotherapeutics Ltd. Pridopidine for use in the treatment of fragile x syndrome
RS67438B1 (sr) 2017-08-14 2025-12-31 Prilenia Neurotherapeutics Ltd Lečenje amiotrofne lateralne skleroze pridopidinom
NL2019473B1 (en) 2017-09-01 2019-03-11 Isobionics B V Terpene Synthase producing patchoulol and elemol, and preferably also pogostol
MX383462B (es) 2017-09-08 2025-03-14 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento de las discinesias inducidas por fármacos

Also Published As

Publication number Publication date
KR20140008297A (ko) 2014-01-21
CN103249697A (zh) 2013-08-14
AU2011298382A1 (en) 2013-05-02
US20160166559A1 (en) 2016-06-16
BR112013005125A2 (pt) 2016-08-16
CN103249697B (zh) 2016-06-15
SG188298A1 (en) 2013-04-30
EA201390332A1 (ru) 2013-08-30
MX2013002453A (es) 2013-08-01
ZA201301902B (en) 2014-05-28
NZ608120A (en) 2014-12-24
CA2810092A1 (en) 2012-03-08
JP2013536825A (ja) 2013-09-26
US20160095847A1 (en) 2016-04-07
US10799492B2 (en) 2020-10-13
CL2013000604A1 (es) 2013-11-15
US20190015401A1 (en) 2019-01-17
PH12013500406A1 (en) 2019-07-17
US20180235950A1 (en) 2018-08-23
SG10201506761XA (en) 2015-10-29
IL224776A (en) 2017-07-31
EP2611759A1 (en) 2013-07-10
AU2016250390A1 (en) 2016-11-10
US20130197031A1 (en) 2013-08-01
WO2012028635A1 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
PE20140105A1 (es) Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos
UY32543A (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
UY32547A (es) Piperidinas sustituidas como antagonistas de ccr3
PE20120648A1 (es) Compuestos de 4-isopropilfenilglucitol como inhibidores de sglt1
CL2011001082A1 (es) Compuestos derivados de amino-tetrahidropiranos sustituidos con heterociclos, composicion farmaceutica; y uso en el tratamiento de una afeccion seleccionada de resistencia a la insulina, hiperglicemia y diabetes de tipo 2.
ECSP13012900A (es) Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos
UY31616A1 (es) Derivados de urea de tetrahidroquinoxalina, su preparación y su aplicación en terapéutica
ECSP12011631A (es) Composición de insulina de acción prolongada
CR10060A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
CO6321232A2 (es) Compuesto de tropano como inhibidores de hsp90
DOP2013000027A (es) Derivados de tetrahidro-pirido-pirimidina
PE20091843A1 (es) Inhibidores de catepsina c
CO6331308A2 (es) Derivados de carboxamidaindazol con actividad sobre el receptor cb1 y composiciones farmaceuticas que los comprenden
EA201290208A1 (ru) Способ лечения андроген-рецептор позитивных раковых заболеваний
ECSP067120A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
PE20151060A1 (es) Nuevos derivados de pirazina como agonistas del receptor cb2
CR11360A (es) Benzotiazoles como moduladores del receptor de grelina
PE20142450A1 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
PE20170427A1 (es) Peptidos como agonistas de la oxitocina
PE20091777A1 (es) Dronedarona o una sal aceptable farmaceuticamente de la misma
ECSP11011415A (es) Piperidinas sustituidas como antagonistas de ccr3.
EA201171289A1 (ru) Композиция для укладки волос
CL2011003123A1 (es) Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras.
DOP2010000156A (es) Oxazolidinonas para el tratamiento y/o profilaxis de la insuficiencia cardiaca
ECSP10010642A (es) Derivados de arilpirazinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso para el tratamiento de diabetes

Legal Events

Date Code Title Description
FC Refusal